Core Viewpoint - Certara, Inc. will release its financial results for Q2 2025 on August 6, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Investor Information - Investors interested in the conference call must register online, with a recommendation to do so at least one day in advance [1]. - A live and archived webcast of the conference call will be available on the "Investors" section of Certara's website [2]. Contact Information - Investor Relations contact is David Deuchler from Gilmartin Group [4]. - Media contact is Alyssa Horowitz [4].

Core Viewpoint - Certara, Inc. has reported strong preliminary financial results for Q1 2025, with significant growth in revenue and bookings, and has reiterated its full-year guidance for 2025 [2][6]. Financial Performance - Expected revenue for Q1 2025 is $106.0 million, a 10% increase from $96.7 million in Q1 2024 [7]. - Software revenue is projected at $46.4 million, up 18% from $39.3 million in the same quarter last year [7]. - Services revenue is expected to be $59.6 million, reflecting a 4% growth from $57.3 million in Q1 2024 [7]. - Total bookings for Q1 2025 are anticipated to be $118.0 million, a 12% increase from $105.8 million in Q1 2024 [7]. - Adjusted EBITDA is estimated to be in the range of $33-$35 million, representing a growth of 13-20% compared to $29.1 million in Q1 2024 [7]. Full-Year Guidance - The company maintains its full-year 2025 revenue guidance in the range of $415 million to $425 million [8]. - Adjusted EBITDA margin for the full year is expected to be between 30-32% [8]. - Adjusted diluted earnings per share is projected to be in the range of $0.42 - $0.46 [8]. Strategic Developments - Arsenal Capital Partners has agreed to a one-year lock-up on shares acquired from EQT, indicating continued support for Certara's growth [3][6]. - Certara is actively pursuing a strategic evaluation of its regulatory services business, engaging in preliminary discussions with external parties [9]. Share Repurchase Program - The Board of Directors has authorized a stock repurchase program allowing for the repurchase of up to $100 million of outstanding common stock, reflecting confidence in the company's strategy [2][3].